Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $13.7052W HIGH $30.99
Volume
715.97 K
Value Traded
26.47 M
Short % Float
25.72%
+1.21%Week
-24.24%1 Month
-37.83%3 Month
-20.96%6 Month
-17.41%5 Year
-17.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.16 B
EPS (TTM)
-2.80
P/E Ratio
-
Ent. Value
660.77 M
Total Shares
66.17 M
Float Shares
43.52 M
Insiders
34.23%
Institutions
77.37%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
BCAX Catalyst Timeline
Dated clinical, regulatory and corporate events for Bicara Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bicara Therapeutics Inc.
86Total events
9Upcoming
11Tier-1 (high impact)
2024 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Trial Initiationficerafusp alfaTrial
Initiate randomized study of ficerafusp alfa with pembrolizumab loading and Q3W maintenance regimen
1L R/M HPV-negative HNSCCsource ↗
◆Oral Presentationficerafusp alfaPresentation
Present long-term follow-up data from Phase 1b at ASCO 2026
1L R/M HPV-negative HNSCCsource ↗
◆Oral Presentationficerafusp alfaPresentation
ASCO 2026 poster presentation: Sustained Depth and Durability of Response with TGF-β Trapping
1L R/M HPV-negative HNSCCsource ↗
◆Oral Presentationficerafusp alfaPresentation
Present long-term follow-up data from Phase 1b expansion cohorts at ASCO 2026
1L R/M HPV-negative HNSCCsource ↗
▲Full Resultsficerafusp alfaClinical Data
Extended follow-up data out to three years from Phase 1/1b study of ficerafusp alfa plus pembrolizumab
1L R/M HPV-negative HNSCCsource ↗
▲Publicationficerafusp alfaPresentation
Publication of Phase 1b expansion cohort results in Journal of Clinical Oncology
1L R/M HNSCCsource ↗
●Management ChangeCorporate
Bill Schelman promoted to CMO, David Raben transitions to Senior Executive Advisor
◆Long Term Dataficerafusp alfaClinical Data
Long-term follow-up data from Phase 1b study of ficerafusp alfa + pembrolizumab
1L R/M HPV-negative HNSCCsource ↗
▲Oral Presentationficerafusp alfaPresentation
Presented Phase 1b data at 2026 Multidisciplinary Head and Neck Cancers Symposium
1L R/M HPV-negative HNSCCsource ↗
▼Equity OfferingCorporate
Raised $161.8 million net proceeds from oversubscribed public offering
▼Equity OfferingCorporate
Closing of oversubscribed public offering and full exercise of underwriters' option
▼Equity OfferingCorporate
Pricing of $150 million public offering of common stock and pre-funded warrants
▲Dose Finding Updateficerafusp alfaTrial
Selected 1500 mg QW of ficerafusp alfa in combination with pembrolizumab as optimal dose for Phase 3 FORTIFI-HN01
1L HPV-negative R/M HNSCCsource ↗
◆Timing Guidanceficerafusp alfaPresentation
Optimal dose declaration for pivotal FORTIFI-HN01 study expected
first-line recurrent/metastatic head and neck squamous cell carcinomasource ↗
◆Topline Readoutficerafusp alfaClinical Data
Data from exploratory Phase 1b expansion cohort (2000 mg Q2W) in 1L HPV-negative R/M HNSCC
1L HPV-negative R/M HNSCCsource ↗
◆Oral Presentationficerafusp alfaPresentation
Data from 2000mg every other week cohort expected at medical meeting
1L R/M HNSCC (HPV-negative)source ↗
▲Dose Finding Updateficerafusp alfaTrial
Selected 1500mg weekly of ficerafusp alfa as optimal dose for Phase 3
1L R/M HPV-negative HNSCCsource ↗
▲Trial Initiationficerafusp alfaTrial
Initiated Phase 3 of FORTIFI-HN01 pivotal trial
1L R/M HPV-negative HNSCCsource ↗
▲Oral Presentationficerafusp alfaPresentation
Presented Phase 1b data at ESMO Asia Congress 2025
1L R/M HPV-negative HNSCCsource ↗
◆Oral Presentationficerafusp alfaPresentation
Preliminary Phase 1b expansion cohort data for 750mg ficerafusp alfa weekly plus pembrolizumab presented at ESMO Asia
first-line human papillomavirus (HPV)-negative recurrent/metastatic head and neck squamous cell carcinomasource ↗
◆Oral Presentationficerafusp alfaPresentation
Data from Phase 1b expansion cohort evaluating 750mg ficerafusp alfa weekly + pembrolizumab expected at ESMO Asia 2025
1L HPV-negative R/M HNSCCsource ↗
◆Abstractficerafusp alfaPresentation
Abstract published with preliminary Phase 1b expansion cohort data for 750mg ficerafusp alfa weekly plus pembrolizumab
1L HPV-negative R/M HNSCCsource ↗
▲Breakthrough Therapy Designationficerafusp alfaDesignation
FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC
1L HPV-negative R/M HNSCCsource ↗
▲Breakthrough Therapy Designationficerafusp alfaDesignation
FDA grants Breakthrough Therapy Designation to ficerafusp alfa in combination with pembrolizumab for 1L HPV-negative R/M HNSCC
1L HPV-negative R/M HNSCCsource ↗
◆Oral Presentationficerafusp alfaPresentation
Data from 750mg weekly cohort expected at medical meeting
1L R/M HNSCC (HPV-negative)source ↗
◆Oral PresentationPresentation
Participation in upcoming investor conferences with fireside chats
◆Oral PresentationPresentation
Fireside chat at Goldman Sachs 46th Annual Global Healthcare Conference
▲Oral Presentationficerafusp alfaPresentation
Updated data presented at ASCO 2025 for ficerafusp alfa plus pembrolizumab in 1L R/M HNSCC
first-line recurrent/metastatic head and neck squamous cell carcinoma (HPV-negative)source ↗
◆Quarterly UpdateCorporate
Company conference call to present fulsome dataset from Phase 1/1b trial
▲Full Resultsficerafusp alfaClinical Data
Updated Phase 1/1b results for ficerafusp alfa plus pembrolizumab
first-line recurrent/metastatic head and neck squamous cell carcinoma (HPV-negative)source ↗
◆Oral Presentationficerafusp alfaPresentation
Updated data from ongoing Phase 1/1b trial of ficerafusp alfa in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting
1L R/M HNSCCsource ↗
◆Abstractficerafusp alfaPresentation
Abstract with updated interim data from Phase 1/1b trial of ficerafusp alfa in combination with pembrolizumab published on ASCO website
first line recurrent/metastatic head and neck squamous cell carcinomasource ↗
▲Enrollment Completeficerafusp alfaTrial
Cohort evaluating 750mg ficerafusp alfa weekly + pembrolizumab in HPV-negative patients completed enrollment
1L R/M HNSCC (HPV-negative)source ↗
◆Poster Presentationficerafusp alfaPresentation
Ficerafusp alfa reverses acquired resistance to sotorasib in KRAS-G12C-mutated lung tumors
KRAS-G12C-mutated lung tumorssource ↗
◆Oral Presentationficerafusp alfaPresentation
Multiple presentations at AACR 2025
solid tumorssource ↗
▲Topline Readoutficerafusp alfaClinical Data
Dose expansion results of single agent ficerafusp alfa in metastatic or advanced cSCC
cutaneous squamous cell carcinoma (cSCC)source ↗
Past FDA Catalysts and PDUFA Decisions
How BCAX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-29 | ficerafusp alfa (with pembrolizumab) | Phase 1b data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$150M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 44%
Micro Cap(rank 291 of 660)
Percentile Rank
Bicara Therapeutics Inc. faces pipeline headwinds (38/100), with $376M risk-adjusted pipeline value, led by Ficerafusp alfa in Head and Neck Squamous Cell Carcinoma (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ficerafusp alfa Small moleculeNCT06788990 | Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | RECRUITING | 810 | Jul 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every BCAX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ficerafusp alfa Breakthrough | recurrent/metastatic HPV-negative head and neck squamous cell carcinoma | Phase 1/1b | 2026-05-22 | overall survival rate: 31%; complete response rates: 750mg QW 13%, 1500mg QW 25%, 2000mg Q2W 30%Read More | Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCCRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Cohlhepp RyanDirector, Officer (President, COO & Interim CEO) | Option | 17,500 199,141 held | $3.79 | 09/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BCAX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 1.9 % (26.7 %) | 215.43 M | 7.26 M |
BCAX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BCAX ranks across every disease it competes in
Competitive Position is a premium feature
See how BCAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBCAX News
BCAXBicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics has announced the awarding of inducement grants to two new employees as part of its 2026 Inducement Plan. The grants include non-qualified stock options to purchase a total of 207,150 shares at an exercise price of $18.20. This initiative aims to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4). Bicara is dedicated to developing transformative therapies for solid tumors.
Read more →BCAXBicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced the awarding of inducement grants to two new employees under its 2026 Inducement Plan. The grants include non-qualified stock options totaling 380,575 shares, with a significant portion going to the newly appointed Chief Legal Officer. These awards are part of Bicara's strategy to attract talent and are compliant with Nasdaq Listing Rule 5635(c)(4).
Read more →BCAXBicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced the awarding of a stock option grant to Jennifer Larson as part of her employment as Chief Financial Officer. The inducement grant consists of 285,000 shares with a vesting schedule tied to her continued service. This grant is part of Bicara's 2026 Inducement Plan and complies with Nasdaq regulations.
Read more →BCAX▼ -14.3%on this news
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
Bicara Therapeutics has announced significant leadership changes, with Ryan Cohlhepp appointed as the new CEO effective January 2027. Claire Mazumdar will transition to Vice Chair of the Board and serve as a Strategic Advisor. The company is also on track for substantial enrollment in pivotal trials, indicating positive progress in their operations.
Read more →BCAXBicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. will report its second quarter 2026 financial results and business updates on August 11, 2026. A conference call is scheduled for 8:30 AM ET to discuss these updates. The company is focused on developing bifunctional therapies for solid tumors, particularly highlighting its lead program, ficerafusp alfa.
Read more →BCAXBicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
Bicara Therapeutics has appointed Jeremy Bender and Christy Oliger to its Board of Directors, enhancing its leadership team. Bender, with over 20 years in biotechnology, and Oliger, with extensive experience in biopharmaceuticals, are expected to provide valuable insights as Bicara advances its clinical-stage initiatives. The company also acknowledges the retirement of founding member Kiran Mazumdar-Shaw.
Read more →BCAXFicerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
Bicara Therapeutics announced promising three-year follow-up data for ficerafusp alfa in combination with pembrolizumab for first-line treatment of recurrent/metastatic HPV-negative head and neck squamous cell carcinoma. The study demonstrated a 31% overall survival rate, doubling the survival compared to standard treatments. The therapy showed deep and durable responses, supported by a favorable safety profile.
Read more →BCAX▼ -6.2%on this news
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced the awarding of a stock option grant to Christopher Sarchi, its new Chief Commercial Officer, as part of its 2026 Inducement Plan. The grant includes 282,240 shares with a vesting schedule tied to his continued employment. This move is part of Bicara's strategy to enhance its leadership as it develops bifunctional therapies for solid tumors.
Read more →BCAXBicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Bicara Therapeutics reported its Q1 2026 financial results, highlighting advancements in their pivotal trial for ficerafusp alfa in HPV-negative head and neck cancer. The company plans to initiate a new randomized study in Q3 2026, aiming for accelerated FDA approval. Additionally, executive leadership changes were announced to support commercialization efforts.
Read more →BCAXBicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. will report its first quarter 2026 financial results and business updates on May 11, 2026, at 8:30 AM ET. The company is focused on developing bifunctional therapies for solid tumors, particularly through its lead program, ficerafusp alfa. This therapy aims to improve patient outcomes in head and neck squamous cell carcinoma and other solid tumors.
Read more →BCAXBicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Bicara Therapeutics announced its fourth quarter and full year 2025 financial results, reporting significant progress in the development of its treatment ficerafusp alfa for HPV-negative head and neck cancer. The company initiated Phase 3 of the pivotal FORTIFI-HN01 trial with promising interim findings expected by mid-2027. It successfully raised $161.8 million to bolster its medical infrastructure and product development efforts. However, rising operational losses and R&D expenses signal financial risks that could affect future viability.
Read more →BCAXBicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. will report its fourth quarter and full year 2025 financial results on March 30, 2026, before the market opens. A conference call will be held at 8:30 AM ET to discuss these results and business updates. The company focuses on innovative bifunctional therapies for solid tumors, particularly with its lead program, ficerafusp alfa.
Read more →BCAXBicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Bicara Therapeutics announced the closing of its public offering, raising approximately $172.5 million through the sale of 8,581,250 shares and 2,200,000 pre-funded warrants. The offering was oversubscribed, reflecting strong investor interest. Proceeds from the offering will be utilized to enhance its medical infrastructure, support a regulatory filing for ficerafusp alfa, and further its clinical development programs. Bicara focuses on creating therapies for solid tumors, specifically targeting unmet needs in head and neck cancers.
Read more →BCAX▲ +7.8%on this newsshared move
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
Bicara Therapeutics has announced the pricing of a $150 million public offering of common stock and pre-funded warrants. The offering includes 7,175,000 shares priced at $16.00 each, with additional pre-funded warrants available. The company plans to use the proceeds to enhance its infrastructure and support the development of its lead therapy, ficerafusp alfa, for solid tumors. The offering is expected to close on February 26, 2026.
Read more →BCAX▲ +7.8%on this newsshared move
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
Bicara Therapeutics has announced a proposed public offering of $150 million in common stock, with an additional option for underwriters to purchase $22.5 million more. The funds will support the development and commercialization of ficerafusp alfa, a bifunctional therapy for solid tumors. The offering is contingent on market conditions and regulatory approvals.
Read more →BCAX▲ +5.9%on this newsshared move
Bicara Therapeutics to Participate in Upcoming Investor Conferences
Bicara Therapeutics Inc. announced its participation in several upcoming investor conferences, including fireside chats in Boston and Miami. The company aims to showcase its innovative bifunctional therapies, particularly ficerafusp alfa, a first-in-class treatment for solid tumors. Live webcasts of these events will be available on their website.
Read more →About Bicara Therapeutics Inc.
Headquarters116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
BIOPHARMAWATCH ELITE PLUS
Trade the next BCAX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime